Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI Summary - About
Janux Therapeutics Inc(JANX)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for JANX
10/16/2026: JANX (2-star) is currently NOT-A-BUY. Pass it for now.
Janux Therapeutics is a clinical-stage biotechnology company focused on creating next-generation T cell engagers to treat solid tumors. Its primary strength lies in its proprietary TRACTr and PRACTr platforms, which aim to improve drug safety by activating therapy only within the tumor microenvironment. The company's growth story is driven by the potential for these novel therapies to address high-unmet needs in oncology, though it faces significant execution and binary risks associated with clinical development. While the company holds a promising technological position, it is currently pre-revenue and speculative. Investors should monitor clinical data readouts and potential licensing deals, while acknowledging that this stock is best suited for those comfortable with high volatility.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Strong fit | The company offers high growth potential linked to the success of its innovative oncology platform. |
| Momentum investor | Mixed fit | Momentum is highly dependent on clinical trial results and positive news flow, making it a conditional play. |
| Value investor | Weak fit | As a pre-revenue company, traditional valuation metrics like P/E ratios are not applicable. |
| Dividend investor | Weak fit | The company does not pay dividends and focuses all capital on pipeline development. |
| Low-risk investor | Weak fit | Clinical-stage biotechnology carries significant binary risk and high price volatility. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | The stock is susceptible to sharp price swings based on clinical data releases. |
| Valuation risk | Medium / high | Valuations in early-stage biotech are often speculative and based on future expectations. |
| Competition risk (Oncology T cell engagers) | High | Established giants have significant resources to challenge Janux's technology. |
| Business quality | Medium | The quality of the R&D platform is high, but the lack of commercial product limits current business maturity. |
| Dividend income | Low / none | There is no income generation for shareholders. |
| Execution risk | High | Success depends entirely on the ability to conduct trials and achieve regulatory approvals. |
Price Behavior
Hockey-Stick Growth
The stock demonstrates a Hockey-Stick Growth price path pattern.
Moderately Choppy
The stock has experienced noticeable price swings while retaining some directional structure.
Analysis of Past Performance
Type Stock | Historic Profit 42.75% | Avg. Invested days 32 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  2.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 10/16/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.01B USD | Price to earnings Ratio - | 1Y Target Price 36.24 |
Price to earnings Ratio - | 1Y Target Price 36.24 | ||
Volume (30-day avg) 905.3K shares | Beta 2.39 | 52 Weeks Range 12.12 - 35.34 | Updated Date 10/18/2026 |
52 Weeks Range 12.12 - 35.34 | Updated Date 10/18/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.64 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Clinical Development | Advancing TRACTr and PRACTr candidates through clinical trials. | Janux is a research-focused firm that aims to profit by eventually licensing or commercializing novel cancer therapies. |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 60.06M | Price to Sales(TTM) 42.06 |
Enterprise Value 60.06M | Price to Sales(TTM) 42.06 | ||
Enterprise Value to Revenue 2.5 | Enterprise Value to EBITDA -33.8 | Shares Outstanding 61.14M | Shares Floating 42.53M |
Shares Outstanding 61.14M | Shares Floating 42.53M | ||
Percent Insiders 0.99 | Percent Institutions 101.21 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.